Reuters · October 14, 2026

Vanda Says Drug VQW-765 Failed Main Goal of Late-Stage Social Anxiety Study; Program Put on Hold

• Vanda Pharmaceuticals said on Wednesday that its experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study, and that the company put the program on hold pending further analysis of the data.
• The study did not show that the drug reduced anxiety compared with placebo during a public-speaking stress test, and it also missed a key secondary goal in the broader study population, the company said.
• The trial enrolled 546 adults with social anxiety disorder at about 30 sites across the United States, according to the report.
• The study was designed to confirm findings from an earlier mid-stage trial; the late-stage results did not confirm those earlier findings, the company said.
• The company said the drug was safe and well tolerated, consistent with prior studies.
• Shares of Vanda were down about 17% in extended trading, according to the report.

Study results, enrollment and program status as stated by Vanda Pharmaceuticals, cited in the original report. Original headline: "Vanda says anxiety drug failed main goal of late-stage study, puts program on hold".